Drugs / Qdenga
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Qdenga | — | 2022-12-05 | europa.eu ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06837116 | Apr → Aug 2025 | dengue disease | Prince of Songkla University | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Qdenga | “Immunogenicity of an Intradermal Qdenga Vaccine Among Healthy Volunteers” NCT06837116 ↗ |
| Modality | Vaccine | “Qdenga Vaccine” NCT06837116 ↗ |
| Route | Subcutaneous | “Subcutaneous route” NCT06837116 ↗ |